Conditions: Pancreatic Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 89
Healthy volunteers: no

Brief summary:
The trial is conducted in order to evaluate the efficacy, safety and pharmacokinetics of BI 2536 in the treatment of unresectable advanced pancreatic cancer as first line or second line therapy. A secondary aim is to identify the most suitable dosage regimen for the further phase II and III clinical programme of BI 2536. To achieve this objective, two dosage regimens are compared in patients receiving first line therapy.

Detailed description:

Arms:
arm 1: Day 1 arm 2: Day 1 - 3

Interventions: intervention 1: BI 2536
Intervention descriptions: intervention 1: Intravenous Infusion

Protocol document: